REGN5713

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Allergic ConjunctivitisAllergic RhinitisConjunctivitis

Phase 2

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

CompletedNCT05430919

Regeneron PharmaceuticalsAllergic Rhinitis, Conjunctivitis

Start: 2022-08-15End: 2023-07-31Updated: 2024-11-19

Phase 3

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

CompletedNCT04709575

Regeneron PharmaceuticalsAllergic Rhinitis, Conjunctivitis

Start: 2021-01-14End: 2021-08-24Updated: 2022-10-27

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

CompletedNCT06602739

Regeneron PharmaceuticalsAllergic Conjunctivitis

Start: 2024-11-19End: 2025-08-02Updated: 2026-04-21

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

TerminatedNCT07309432

Regeneron PharmaceuticalsAllergic Conjunctivitis

Start: 2026-01-10End: 2026-06-15Updated: 2026-09-01